You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm reported $6.3 million in third quarter revenues compared to $2.2 million in the year ago period, but fell short of the consensus Wall Street estimate of $7.5 million.
Abbott said that a lawsuit it filed Thursday tries to obtain important information from Alere before its acquisition is completed.
Encouraged by positive customer feedback from early installations, the firm is shifting its sales focus to the ePlex system and respiratory pathogen panel.
The revenue increase was driven by increased sales of its Afirma gene classifier thyroid test, as well as improved predictability of payments.
The firm said it is on track for solid future growth based on the expectation for new product approvals and continued strength in the CareFusion product portfolio.
Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.
The company beat analysts' consensus estimates on both the top and bottom lines as its molecular diagnostics sales rose 9 percent at constant exchange rates.
The company reported $29.4 million in revenues for the quarter and a net loss of $31.3 million, while the number of clinical tests increased to 11,627.
Despite lower than expected NGS instrument sales, Illumina expects continued growth in the oncology market as reimbursement increases.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.